本文選題：醋酸戈舍瑞林緩釋植入劑 + 前列腺癌��； 參考：《中國臨床藥理學(xué)雜志》2017年14期

【摘要】：目的觀察醋酸戈舍瑞林緩釋植入劑長期應(yīng)用對前列腺癌患者去勢后的臨床療效及安全性。方法 42例前列腺癌患者隨機分為對照組及試驗組,每組21例。雙側(cè)睪丸切除術(shù)后,對照組給予口服比卡魯胺片50 mg qd;試驗組在對照組基礎(chǔ)上加用醋酸戈舍瑞林緩釋植入劑3.60 mg,每28 d一次,腹前壁皮下注射。2組均持續(xù)治療6個月。比較2組患者治療前后血清前列腺特異性抗原、α-甲�；o酶A消旋酶水平、總有效率及安全性。結(jié)果治療后,試驗組和對照組的總有效率分別為90.48%(19/21例)和61.91%(13/21例),差異有統(tǒng)計學(xué)意義(P0.05)。治療后,試驗組和對照組患者血清前列腺特異性抗原(PSA)分別為(6.74±0.73),(13.27±1.17)μg·L-1;α-甲�；o酶A消旋酶(P504S)水平分別為(1.26±0.12),(1.85±0.21)μg·L-1,差異均有統(tǒng)計學(xué)意義(P0.05)。試驗組的藥物不良反應(yīng)主要有潮熱4例,乏力2例,腹瀉1例,乳房腫痛2例,對照組的藥物不良反應(yīng)主要有潮熱3例,乏力3例,乳房腫痛2例。試驗組和對照組的藥物不良反應(yīng)發(fā)生率分別為42.86%(9/21例)和38.09%(8/21例),差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論醋酸戈舍瑞林緩釋植入劑長期應(yīng)用能夠顯著降低前列腺癌患者去勢后患者的血清前列腺特異性抗原、α-甲�；o酶A消旋酶水平,提高臨床療效,安全性較高。
[Abstract]:Objective to observe the efficacy and safety of coserelin acetate sustained release implantation in patients with prostate cancer after castration. Methods 42 patients with prostate cancer were randomly divided into control group and experimental group with 21 cases in each group. After bilateral orchiectomy, the control group was given oral Carous Amine tablet 50mg QD, and the experimental group was treated continuously for 6 months by subcutaneous injection of Goserrelin Acetate 3.60 mg per 28 days on the basis of the control group. The serum prostatic specific antigen and 偽 -formyl coenzyme A racemase levels were compared before and after treatment in two groups. The total effective rate and safety were compared. Results after the treatment, the total effective rates of the test group and the control group were 90.48 / 19 / 21 and 61.91 / 13 / 21, respectively. The difference was statistically significant (P 0.05). After treatment, the serum prostatic specific antigen (PSAs) of patients in the experimental group and the control group were 6.74 鹵0.73, 13.27 鹵1.17 渭 g / L, and the levels of 偽 -formylcoA racemase P504S were 1.26 鹵0.12, 1.85 鹵0.21 渭 g / L, respectively, with statistical significance (P 0.05). There were 4 cases of hot flashes, 2 cases of asthenia, 1 case of diarrhea and 2 cases of breast swelling and pain in the experimental group. The adverse drug reactions in the control group were mainly hot flashes in 3 cases, asthenia in 3 cases, and breast swelling and pain in 2 cases. The incidence of adverse drug reactions in the trial group and the control group were 42.86 / 9 / 21 and 38.09% respectively. There was no significant difference between the two groups in the incidence of adverse drug reactions (P 0.05). Conclusion the long-term application of coserelin acetate implants can significantly reduce the serum prostate-specific antigen and 偽 -formyl coenzyme A racemase level in patients with prostate cancer after castration, and improve the clinical efficacy and safety.
【作者單位】： 內(nèi)江市第一人民醫(yī)院泌尿外科;
【基金】：四川省衛(wèi)生廳科研課題基金資助項目(120466)
【分類號】：R737.25

【參考文獻】

相關(guān)期刊論文 前5條

1 朱永鋒;;多西他賽/米托蒽醌聯(lián)合潑尼松治療激素抵抗性前列腺癌的臨床研究[J];中國臨床藥理學(xué)雜志;2015年09期

2 翟忠奇;羅曉輝;湯正岐;殷鋒彥;鄭超;;晚期前列腺癌間歇與持續(xù)性內(nèi)分泌治療的臨床觀察[J];現(xiàn)代腫瘤醫(yī)學(xué);2015年04期

3 陳漢民;蔡聯(lián)明;劉聯(lián)斌;李榮;;血清PSA聯(lián)合PSAD檢測對前列腺癌的診斷價值[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年07期

4 韓蘇軍;張思維;陳萬青;李長嶺;;中國前列腺癌發(fā)病現(xiàn)狀和流行趨勢分析[J];臨床腫瘤學(xué)雜志;2013年04期

5 徐e，

本文編號：1931351